Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs, focusing on medium and small-cap markets, as well as blue-chip companies and broader investment stories [2][3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - The company utilizes technology to enhance workflows and has a team with decades of expertise [3] - Proactive employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [4]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The RedChip Small Sto ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Ga ...

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology V ...

LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key European Patent entitled: "Compositions Comprising Chemerin ...

Core Insights - OKYO Pharma Limited has been granted a key European Patent for "Compositions Comprising Chemerin Analogs and Methods of Use," which strengthens its intellectual property position in the ocular therapy market [1][2] - The patent relates to novel OK-101 chemerin analogs aimed at treating inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), addressing significant unmet medical needs [1][2] - OK-101 is a lipid-conjugated chemerin peptide agonist designed to enhance the treatment of DED and NCP, showing promising results in preclinical and Phase 2 clinical trials [3][4] Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for DED and NCP, with its shares traded on the NASDAQ Capital Market [4] - The company is advancing its pipeline candidates and exploring strategic partnerships to accelerate development and commercialization [2][4] - OK-101 has demonstrated anti-inflammatory and pain-reducing efficacy in mouse models and has recently completed a Phase 2 trial for DED, with plans for a Phase 2 trial for NCP [3][4]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [1][2] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] - Proactive's news team operates across key finance and investing hubs with offices in London, New York, Toronto, Vancouver, Sydney, and Perth [5] Group 2 - The editorial team, led by Ian Lyall, produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [4] - Proactive covers various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [6] - The company adopts technology and automation, including generative AI, while ensuring all content is edited and authored by humans [7][8]

About Ian Lyall About the publisher Proactive news team spans the world's key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Proactive has always been a forward looking and enthusiastic technology adopter. Proactive will on occa ...